Core Points - Shandong Oriental Ocean Technology Co., Ltd. published its articles of association in September 2025, detailing regulations on company organization, shareholder and management rights and obligations, laying a solid institutional foundation for stable development [1][2] - The company was established through a founding method and registered with the Shandong Provincial Administration for Industry and Commerce, with a registered capital of 1,958.9465 million RMB, and was listed on the Shenzhen Stock Exchange on November 28, 2006 [1] - The company operates in various fields including marine aquaculture, food processing, aquatic technology research and promotion, import and export business, freight forwarding, warehousing leasing, and biopharmaceutical research and production [1] Governance Structure - The articles of association specify the issuance, increase, decrease, repurchase, and transfer of shares, with a total of 1,958,946,500 shares, all of which are RMB ordinary shares, adhering to principles of openness, fairness, and justice [1] - The shareholders' meeting is the power institution, responsible for electing directors, reviewing profit distribution plans, and deciding on major company matters, while the board of directors, consisting of nine members, is responsible for operational decisions and management [1] - The company has established a party organization, clarifying its structure and responsibilities, playing a political core role in the company's development [1] Financial Accounting System - The company is required to prepare and disclose annual and interim reports, distribute profits according to regulations, and allocate statutory and discretionary reserves, with a profit distribution policy that emphasizes investor returns while balancing shareholder interests and company development [2] - The publication of the articles of association will help standardize company operations, protect the legitimate rights and interests of shareholders, employees, and creditors, and provide a solid institutional guarantee for long-term development [2]

2025年10月7日，诺诚健华全资子公司InnoCare Pharma Inc.与美国生物制药公司Zenas BioPharma, Inc.签 署授权许可协议。Zenas将获得奥布替尼等产品多项权利，公司保留部分权利。Zenas支付1亿美元首付 款和近期里程碑付款，授予700万普通股股票，交易总额超20亿美元，公司还可按净销售额收特许权使 用费。协议签署将加快产品全球开发和商业化，预计利好未来业绩。不过，新药研发风险高、周期长， 交易付款有条件，金额存不确定性，投资者需防范风险。 ...

整理 | GLP1减重宝典内容团队 自去年尼马昔单抗在一项中期研究中失败后，Skye 停止了其眼部疾病候选药物的开发，此后该公司一直寄希望于尼马昔单抗（一种每 周皮下注射的药物）来推动增长。 尼马昔单抗旨在阻断有助于分解储存脂肪和调节食欲相关激素的 CB1 蛋白，从而有助于持续减重而不损失肌肉。 Skye Bioscience (SKYE.O) 的实验性疗法在一项中期研究中未能实现显著降低肥胖成年人体重的主要目标，导致其股价周一下跌逾 60%。 接受尼马昔单抗 (nimacimab) 治疗的患者在调整安慰剂率后，体重减轻了 1.26%，低于该公司预期的 5% 至 8%。 "虽然我们仍然对 Skye 靶向 CB1 的方法很感兴趣，但从今天报告的数据来看，我们仍未确信这一点，"Cantor 分析师 Kristen Kluska 表示。她补充说，如果更高的剂量能够带来足够的减重效果，从而具有竞争力，那么这仍是一个"让我看看的故事"。 Skye 表示，在研究中，尼马昔单抗并未观察到与此类药物相关的神经精神问题。 "我们已经找到了一个解决方案，可以解决迄今为止困扰该机制的安全问题，"首席执行官 Punit Dhillo ...

公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 (HLX03)、贝伐珠单抗汉贝泰(HLX04)，进行合作开发，开展本地注册、生产及商业化。另外，此次合 作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共同推动 该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万港元。 ...

公开资料显示，2024年11月，复宏汉霖与沙特阿拉伯SVax公司达成战略合作。双方将在沙特阿拉伯分 别设立商业化和生产合资公司，并在MENAT地区就复宏汉霖的一系列产品，包括阿达木单抗汉达远 （HLX03）、贝伐珠单抗汉贝泰（HLX04），进行合作开发，开展本地注册、生产及商业化。另外， 此次合作框架中的首批项目亦包括共同投资开发复宏汉霖自研的帕博利珠单抗生物类似药HLX17，共 同推动该产品的全球注册上市。 消息面上，复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达正式揭 牌，标志着其在中东地区的本土化运营迈出关键一步。该合资公司由复星医药旗下复宏汉霖与沙特领先 药企SVax共同组建，将整合全球研发资源与本地化优势，为中东、北非及土耳其地区患者提供可负担 的高品质生物药。 智通财经APP获悉，复宏汉霖(02696)现涨超10%，截至发稿，涨9.33%，报77.95港元，成交额8233.55万 港元。 ...

Core Viewpoint - The announcement of the Nobel Prize in Physiology or Medicine is expected to ignite a surge in the research and development of Treg cell therapy technologies and innovative drugs [1] Company Summary - HBM4003, a next-generation antibody targeting the CTLA-4 pathway developed by the company, has shown excellent safety characteristics in clinical studies and has demonstrated clear efficacy signals in multiple tumor types, including colon cancer, liver cancer, and neuroendocrine tumors [1] - The company's antibody HBM1022, targeting the CCR8 pathway, is considered a highly promising candidate in its pipeline, potentially leading to breakthroughs in tumor immunotherapy [1] Industry Summary - The recent Nobel Prize recognition in the field of "peripheral immune tolerance" is likely to stimulate interest and investment in Treg cell therapies and related innovative treatments within the biopharmaceutical industry [1]

Core Viewpoint - The company, 宜明昂科-B (01541), has seen a significant stock price increase following the announcement of its clinical trial applications for IMM2510, a treatment for immune-resistant non-small cell lung cancer (NSCLC) [1] Group 1: Clinical Trial Developments - The company has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 for treating immune-resistant NSCLC [1] - Two additional Phase III registration clinical trials for different types of lung cancer have also been submitted recently [1] Group 2: Clinical Trial Results - Data from a Phase I study presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immunotherapy, the objective response rate was 35.3% and the disease control rate was 76.5% [1] - The median duration of response was reported at 7.59 months, while the median progression-free survival was 9.4 months [1] Group 3: Future Plans - Based on the promising results, the company plans to further validate the efficacy and safety of IMM2510 through the upcoming Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients [1]

Core Viewpoint - The stock of Iminco-B (01541) has increased by over 9%, currently trading at 15.77 HKD, following the submission of a Phase III clinical trial application for IMM2510 to treat immune-resistant non-small cell lung cancer (NSCLC) [1] Company Developments - Iminco has submitted an application to the National Medical Products Administration for a Phase III clinical trial of IMM2510 aimed at treating immune-resistant NSCLC [1] - The company has also submitted two additional Phase III registration clinical trials for different types of lung cancer [1] Clinical Trial Results - Recent Phase I study data presented at the 2025 World Lung Cancer Conference showed that among 17 evaluable patients with advanced squamous NSCLC who had previously received immunotherapy, the objective response rate and disease control rate for IMM2510 were 35.3% and 76.5%, respectively [1] - The median duration of response was reported at 7.59 months, while the median progression-free survival was 9.4 months [1] - Based on these results, the company plans to further validate the efficacy and safety of IMM2510 through Phase III clinical trials, aiming to provide more effective treatment options for lung cancer patients [1]

（文章来源：每日经济新闻） 每经AI快讯，10月8日，港股和誉-B(02256.HK)早盘涨超8%，截至发稿，涨8.2%，报19.4港元，成交额 5846.51万港元。 ...

同比增长14.8%！——这是日前公布的1—8月份石家庄固定资产投资增速，比去年同期提高了5.1个百分 点。 经济发展的"晴雨表"上，固定资产投资的动向总能折射出区域发展的底气与潜力。14.8%的增速，分别 高于全国、全省14.3和8.6个百分点。 稳快增长从何而来？ 今年以来，石家庄牢牢把握高质量发展首要任务，聚焦年度投资目标任务，系统谋划、提前储备、加快 前期、优化服务，全力以赴推动投资项目建设。一个个规模大、质量高、带动力强的项目加速推进，一 批批高端化、智能化、绿色化产业集聚发展，迸发出助推全市经济社会高质量发展的"新引擎"和"硬支 撑"。 大项目支撑 发展后劲足 初秋的石家庄，处处涌动着建设热潮。 步入泰威航科全动模拟器生产基地项目的建设现场，只见一号检测楼已封顶，主体生产车间、仓库正在 进行钢结构安装……这个总投资30亿元的省重点项目，预计明年3月竣工投产，可每年生产约10台D级 全动模拟器，年产值超10亿元。 塔吊巨臂挥舞，运输车辆穿梭，焊接火花四溅……走进河北高速集团电子科技产业园项目现场，热火朝 天的繁忙景象扑面而来。项目布局了研发孵化楼、独立厂房、中试车间等49栋多元建筑，积极服务京津 冀协 ...